Aligos Therapeutics Q4 net loss narrows

Overview

• Biotechnology firm's Q4 net loss narrowed significantly compared to the previous year

• Aligos advanced ALG-170675 into IND-enabling studies with Amoytop

Outlook

• Aligos expects funding to last into Q3 2026

Result Drivers

• HIGHER R&D EXPENSES: Research and development (R&D) expenses for the three months ended December 31, 2025 were $17.0 million, compared with $16.0 million for the same period of 2024.

• LOWER GENERAL AND ADMINISTRATIVE (G&A) EXPENSES: General and administrative (G&A) expenses for the three months ended December 31, 2025 were $4.9 million, compared with $5.2 million for the same period of 2024.

Company press release: ID:nGNXDXNVG

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Aligos Therapeutics Inc is $50.00, about 628.9% above its March 4 closing price of $6.86

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.